FDA rejects Biocon Biologics BLA for Insulin-R product

TAGS

Biocon Limited, an Indian biopharma company, said that its subsidiary has been issued a complete response letter (CRL) from the (FDA) for the biologics license application (BLA) for the product.

The FDA has rejected the BLA seeking more data to support its submission and an expectation of satisfactory implementing a corrective and preventive actions (CAPA) plan regarding the pre-approval inspection of Limited’s facilities in August 22.

FDA rejects Biocon Biologics BLA for Insulin-R product

FDA rejects Biocon Biologics BLA for Insulin-R product. Photo courtesy of Biocon.

A company spokesperson of Biocon Biologics said: “We are in the process of comprehensively addressing the CRL.”

See also  Boston Scientific wraps up $4.2bn acquisition of BTG

In late 2022, Biocon Biologics completed the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This